Clinical trial

Synthetic vs Natural Estrogen in Combined Oral Contraception- Effect on Insulin Sensitivity, Coagulation, Inflammation and Endometrium - a Comparison With a Progestin-only Preparation.

Name
SYLVI030785
Description
The main objective of the study is to compare the metabolic effects of natural estradiol and synthetic ethinylestradiol used in combined oral contraception in healthy women. A progestin-only preparation will be used in comparison. The main goal is to study the effects on glucose metabolism, coagulation and a markers of chronic inflammation (such as hs-CRP). Our hypothesis is that the natural estradiol preparation will influence blood glucose levels, markers of coagulation and chronic inflammation less than the ethinylestradiol preparation. The progestin-only preparation will not effect these parameters.
Trial arms
Trial start
2015-04-01
Estimated PCD
2018-12-30
Trial end
2018-12-30
Status
Completed
Phase
Early phase I
Treatment
Ethinyl estradiol / dienogest
One tablet orally for 9 weeks, continuous use
Arms:
Synthetic estrogen + progestin
Other names:
Valette, ATC code G03AA
Estradiol valerate / dienogest
One tablet orally for 9 weeks, continuous use
Arms:
Natural estrogen + progestin
Other names:
Qlaira, ATC code G03AB08
Dienogest
One tablet orally for 9 weeks, continuous use
Arms:
Progestin-Only
Other names:
Visanne, ATC code G03D
Size
59
Primary endpoint
Matsuda Index- Whole Body Insulin Sensitivity Index
We calculated the change in Matsuda index from baseline to 9 weeks.
Eligibility criteria
Inclusion Criteria: * BMI 19-24.9, regular menstrual cycles (21-35 days), a minimum of 2 months without any hormonal contraceptives, no contraindications for use of hormonal contraception Exclusion Criteria: * Polycystic ovaries, hypertension, smoking, alcohol abuse, pregnancy, lactation, abnormal result in pre-screening 2h oral glucose tolerance test, regular medications
Protocol
{'studyType': 'INTERVENTIONAL', 'phases': ['PHASE4'], 'designInfo': {'allocation': 'RANDOMIZED', 'interventionModel': 'PARALLEL', 'primaryPurpose': 'OTHER', 'maskingInfo': {'masking': 'NONE'}}, 'enrollmentInfo': {'count': 59, 'type': 'ACTUAL'}}
Updated at
2023-06-22

1 organization

3 products

1 indication

Indication
Contraception
Product
Dienogest